BusinessUK

Wellcome Trust launches Venture Capital arm

21.03.2012 - The British Wellcome Trust announced on 20 March that it will launch a £200m business to invest directly in healthcare and life sciences companies. The business, up to now running under its working title Project Sigma, will draw its initial capital from the trust’s endowment.

„Although Sigma has the primary goal of generating excellent returns for the Wellcome Trust, its investments will also provide emerging businesses in the healthcare sector with a valuable new source of funding and guidance“, the Wellcome Trust stated. In recent years, the charity, which hands out £600 million in research grants every year and has a £14 billion endowment, has substantially increased its private equity holdings. On 30 September 2011 it has invested £2.7bn in venture capital firms. The trust has recruited Martin Murphy, previously a partner at venture capital firm MVM Life Science Partners, as Sigma’s chief executive and Oxford Instruments and Deltex Medical chairman Nigel Keen to chair Sigma’s board. As everywhere, British biotech start-ups are struggling to find new funding, and venture capital players have been called conservative in their investments in drug developers in recent years. Therefore, new funding mechanisms are met with cheers. Glyn Edwards, interim chief executive at the BioIndustry Association trade body, expects a significant boost to companies developing new medicines: „It is especially pleasing to see that the fund will take a long term view and provide companies with the support they need to reach their full potential.” 

http://www.european-biotechnology-news.com/news/news/2012-01/wellcome-trust-launches-venture-capital-arm.html

New reportEU

25.11.2014 The European biotech IPO slump has finally come to an end. A brand new industry report shows that compared to previous years, the number of biotech IPOs more than doubled in 2014, with London and Paris exchanges leading the pack.

M&AIreland

19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.

Drug DevelopmentGermany

18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.

FinanceFrance

14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.

AwardsFranceGermanySweden

12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.

ResearchEU

10.11.2014 EFPIA’s specialised group Vaccines Europe and the Innovative Medicines Initiative (IMI) have launched a €280m Call for proposals aimed to address the Ebola crisis.

Trade fairGermanyEU

07.11.2014 3,200 participants from 54 countries attended the 20th issue of BIO-Europe. The overall mood of the European biotech sector was modestly optimistic.

AcquisitionGermanyUKSweden

05.11.2014 German Definiens AG has a new owner: Astrazeneca’s biologics R&D arm Medimmune has taken over all the shares of the imaging specialist for US$150m.

AcquisitionSwedenDenmarkUK

04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.

FinancingSwedenNorway

31.10.2014 Another biotech is leaving the European market place in favour of a US IPO. Swedish Cortendo is now planning to go public in the US after raising €8.8m in bridge financing.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MEDIGENE3.95 EUR2.33%
  • 4SC0.92 EUR2.22%
  • BIOTEST80.77 EUR1.62%

FLOP

  • CYTOS0.27 CHF-6.90%
  • CO.DON2.56 EUR-3.40%
  • WILEX2.10 EUR-2.78%

TOP

  • CYTOS0.27 CHF58.8%
  • EPIGENOMICS5.20 EUR36.8%
  • FORMYCON10.74 EUR36.1%

FLOP

  • 4SC0.92 EUR-13.2%
  • CO.DON2.56 EUR-12.6%
  • BIOFRONTERA2.59 EUR-9.4%

TOP

  • SANTHERA92.00 CHF2321.1%
  • CO.DON2.56 EUR156.0%
  • BB BIOTECH185.30 EUR63.0%

FLOP

  • CYTOS0.27 CHF-91.9%
  • 4SC0.92 EUR-48.3%
  • THERAMETRICS0.07 CHF-46.2%

No liability assumed, Date: 26.11.2014